Thermo Fisher Scientific Inc (TMO) reported better-than-expected financial results for the third quarter of fiscal 2025. The company achieved earnings per share of $5.79, surpassing Wall Street's consensus estimate of $5.55 by $0.24. Revenue also exceeded expectations, coming in at $11.1 billion compared to the anticipated $11.0 billion.
The results reflect the strength of Thermo Fisher's operations, which serve the scientific community through a range of innovative products and services. The company operates in several segments, including Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. With a market capitalization of $214.19 billion and a P/E ratio of 32.62, Thermo Fisher continues to demonstrate robust financial health.
Management will discuss these results in an upcoming earnings conference call scheduled for before market open. Investors may find value in reviewing the full earnings release and listening to management's commentary for further context on the quarter’s performance and future outlook.
Looking ahead, Thermo Fisher is expected to report its next earnings on July 20, 2026, with an estimated EPS of $5.9262 and revenue of $11.5 billion. This update provides insight into the company's ongoing operational performance and its position within the life sciences tools and services industry.